Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberonics’ VNS Therapy Approvable As Last-Resort Depression Fix – Panel

This article was originally published in The Gray Sheet

Executive Summary

FDA's Neurological Devices Panel set aside its desire for an additional, randomized trial of Cyberonics' VNS Therapy depression indication at a June 15 meeting to review the device in Gaithersburg, Md
Advertisement

Related Content

SEC investigates Cyberonics
Schultz’ Controversial Approval Of Cyberonics Device Has Little Precedent
FDA’s Second-Guessing Of Device Applications Spurs Public Citizen Protest
Cyberonics Depression Approval Contingent On Dosing Trial, Registry
Rejected Device Applicants Conserve R&D Resources, Sidestep Confrontation
Cyberonics Banking On Appeals To Avoid VNS Randomized Trial Requirement
Randomization Unethical For VNS Depression Patients, Cyberonics Says
Favorable FDA Panel Reviews Propel Biomet, Cyberonics Stocks In June
Alzheimer’s May Be Cyberonics’ New Frontier; Trial Costs Projected
Cyberonics Expects VNS Will Capture 4% Of U.S. Depression Market By 2010
Advertisement
UsernamePublicRestriction

Register

MT020423

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel